Unknown

Dataset Information

0

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.


ABSTRACT: Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function and improved patient survival. For this purpose, we developed the selective anti-ATTR antibody NI301A, a recombinant human monoclonal immunoglobulin G1. NI301A was cloned following comprehensive analyses of memory B cell repertoires derived from healthy elderly subjects. NI301A binds selectively with high affinity to the disease-associated ATTR aggregates of either wild-type or variant ATTR related to sporadic or hereditary disease, respectively. It does not bind physiological transthyretin. NI301A removes ATTR deposits ex vivo from patient-derived myocardium by macrophages, as well as in vivo from mice grafted with patient-derived ATTR fibrils in a dose- and time-dependent fashion. The biological activity of ATTR removal involves antibody-mediated activation of phagocytic immune cells including macrophages. These data support the evaluation of safety and tolerability of NI301A in an ongoing phase 1 clinical trial in patients with ATTR cardiomyopathy.

SUBMITTER: Michalon A 

PROVIDER: S-EPMC8149704 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.

Michalon Aubin A   Hagenbuch Andreas A   Huy Christian C   Varela Evita E   Combaluzier Benoit B   Damy Thibaud T   Suhr Ole B OB   Saraiva Maria J MJ   Hock Christoph C   Nitsch Roger M RM   Jan Grimm  

Nature communications 20210525 1


Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function and improved patient survival. For this purpose, we developed the selective anti-ATTR antibody NI301A, a recombinant human monoclonal immunoglobulin G1. NI301A was cloned following comprehensive anal  ...[more]

Similar Datasets

| S-EPMC9147607 | biostudies-literature
| S-EPMC4940135 | biostudies-literature
| S-EPMC8039703 | biostudies-literature
| S-EPMC4036335 | biostudies-literature
| S-EPMC7306164 | biostudies-literature
| S-EPMC7229108 | biostudies-literature
| S-EPMC6055172 | biostudies-literature
| S-EPMC3386102 | biostudies-literature
| S-EPMC6032350 | biostudies-literature
| S-EPMC8825236 | biostudies-literature